Lyra Therapeutics Inc

NASDAQ:LYRA  
12.97
+0.01 (+0.08%)
Earnings Announcements

Lyra Therapeutics Reports Third Quarter 2020 Financial Results And Provides Corporate Update

Published: 11/10/2020 21:29 GMT
(LYRA) - Lyra Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update.
Lyra Therapeutics - Remains on Track to Announce Topline Phase 2 Results From Lantern Study of Lyr-210 in Chronic Rhinosinusitis (crs) in December.
Lyra Therapeutics Inc Quarterly Loss per Share $0.49.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.58

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.63

More details on our Analysts Page.